Psilocybin and MDMA are poised to be the hottest new therapeutics since Prozac. Universities want in, and so does Wall Street. Some worry a push to loosen access could bring unintended consequences. Open at source
Save highlights in Reader View or with our Chrome extension.
This your link? Claim it
Or use your social account
Have an account? Sign in
Not on Refind yet? Sign up